首页> Haematologica> A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

导出 OA

翻译打印收藏纠错

第一作者： Neha,Korde

第一单位： Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

作者： Neha,Korde ^[1] ; Mattias,Carlsten ^[2] ; Min-Jung,Lee ^[3] ; Alex,Minter ^[4] ; Esther,Tan ^[4] ; Mary,Kwok ^[4] ; Elisabet,Manasanch ^[1] ; Manisha,Bhutani ^[1] ; Nishant,Tageja ^[1] ; Mark,Roschewski ^[1] ; Adriana,Zingone ^[1] ; Rene,Costello ^[1] ; Marcia,Mulquin ^[1] ; Diamond,Zuchlinski ^[1] ; Irina,Maric ^[5] ; Katherine R,Calvo ^[5] ; Raul,Braylan ^[5] ; Prashant,Tembhare ^[6] ; Constance,Yuan ^[6] ; Maryalice,Stetler-Stevenson ^[6] ; Jane,Trepel ^[3] ; Richard,Childs ^[2] ; Ola,Landgren ^[7]

作者单位： Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[1] Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. ^[2] Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[3] Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA. ^[4] Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. ^[5] Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[6] Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA landgrec@mskcc.org. ^[7]

关键词 HLA-C binding KIR2D reports IPH2101 KIR2D blockade NK-cell function clinical response smoldering multiple myeloma

医学主题词抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);人类(Humans);多发性骨髓瘤(Multiple Myeloma);受体, KIR(Receptors, KIR);治疗结果(Treatment Outcome)

DOI 10.3324/haematol.2013.103085

PMID 24658821

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交